- Home
- NFE vs MYGN Comparison
NFE vs MYGN Comparison
Compare NFE & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- MYGN
- Stock Information
- Founded
- NFE 2014
- MYGN 1991
- Country
- NFE United States
- MYGN United States
- Employees
- NFE N/A
- MYGN N/A
- Industry
- NFE Oil/Gas Transmission
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NFE Utilities
- MYGN Health Care
- Exchange
- NFE Nasdaq
- MYGN Nasdaq
- Market Cap
- NFE 773.2M
- MYGN 642.0M
- IPO Year
- NFE 2019
- MYGN 1995
- Fundamental
- Price
- NFE $2.11
- MYGN $7.65
- Analyst Decision
- NFE Strong Buy
- MYGN Hold
- Analyst Count
- NFE 5
- MYGN 13
- Target Price
- NFE $7.70
- MYGN $13.50
- AVG Volume (30 Days)
- NFE 28.8M
- MYGN 1.5M
- Earning Date
- NFE 11-06-2025
- MYGN 11-06-2025
- Dividend Yield
- NFE N/A
- MYGN N/A
- EPS Growth
- NFE N/A
- MYGN N/A
- EPS
- NFE N/A
- MYGN N/A
- Revenue
- NFE $2,006,240,000.00
- MYGN $832,900,000.00
- Revenue This Year
- NFE $10.40
- MYGN $0.17
- Revenue Next Year
- NFE $11.08
- MYGN $6.19
- P/E Ratio
- NFE N/A
- MYGN N/A
- Revenue Growth
- NFE N/A
- MYGN 3.83
- 52 Week Low
- NFE $1.26
- MYGN $3.76
- 52 Week High
- NFE $16.66
- MYGN $26.52
- Technical
- Relative Strength Index (RSI)
- NFE 45.25
- MYGN 57.23
- Support Level
- NFE $2.10
- MYGN $7.54
- Resistance Level
- NFE $2.66
- MYGN $8.25
- Average True Range (ATR)
- NFE 0.29
- MYGN 0.39
- MACD
- NFE 0.02
- MYGN -0.06
- Stochastic Oscillator
- NFE 16.22
- MYGN 54.77
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.